Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_1

Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

NCT03487055
unknownphase_1

Assessment of Anti-RANKL Antibody in Post-menopausal Women

NCT03242512
unknownphase_1

Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases

NCT03239756

Clinical Trials (3)

Showing 3 of 3 trials
NCT03487055Phase 1

Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

Unknown
NCT03242512Phase 1

Assessment of Anti-RANKL Antibody in Post-menopausal Women

Unknown
NCT03239756Phase 1

Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3